Ectin Research is active in biotechnology. The company specializes in research and development of drug candidates. The research is focused on developing drugs that aim to eliminate cancerous tumors in patients, with the greatest focus on the treatment of bladder cancer. In addition, the company intends to develop drugs for the treatment of breast, colorectal and prostate cancer cells.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Nordnet Pensionsförsäkring | 9,08 | 4,15 | 2021-12-31 |
| JRS Asset Management AB Client Account | 9,05 | 4,14 | 2021-12-31 |
| Peter Falk | 4,35 | 19,63 | 2021-12-31 |
| Ivarsson Medical Research AB | 4,33 | 19,62 | 2021-12-31 |
| Christer Edlund | 4,33 | 19,62 | 2021-12-31 |
| Åke Andersson | 3,85 | 1,76 | 2021-08-03 |
| Power Capital Society AB | 3,49 | 1,60 | 2021-12-31 |
| Moll Invest AB | 3,28 | 1,50 | 2021-12-31 |
| Avanza Pension | 3,00 | 1,37 | 2021-12-31 |
| GU Ventures | 2,70 | 1,23 | 2021-12-31 |
2022-02-22 Bokslutskommuniké 2021
2022-05-17 Delårsrapport 2022-Q1
2022-05-20 Årsstämma 2021
2022-08-23 Delårsrapport 2022-Q2
2022-11-22 Delårsrapport 2022-Q3